rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ansbert Gadicke

10% owner

Company insider

Files Form 4 as: 10% owner, Aktis Oncology; Director and 10% owner, Tcr2 Therapeutics; Director and 10% owner, Kalaris Therapeutics; Director and 10% owner and Other, Cullinan Therapeutics; Director and 10% owner, iTeos Therapeutics; 10% owner, Repare Therapeutics; 10% owner, Harpoon Therapeutics; 10% owner, Oncorus.

Every Form 4 they filed

In numbers

Trades disclosed
392
Buys
15
Sells
88
Bought
$111.8M
Sold
$101.2M
Companies
26
Companies where not an officer
26
First trade
18 Oct 2006
Last trade
12 Jan 2026
Last filed
14 Jan 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
AKTS Aktis Oncology10% owner · Biotechnology · last 12 Jan 20261 buy · 0 sells
Tcr2 TherapeuticsDirector, 10% owner · last 1 Jun 20231 buy · 1 sell
KLRS Kalaris TherapeuticsDirector, 10% owner · Biotechnology · last 28 Jul 20220 buys · 0 sells
CGEM Cullinan TherapeuticsDirector, 10% owner, Other · Biotechnology · last 22 Jun 20221 buy · 18 sells
iTeos TherapeuticsDirector, 10% owner · last 5 Jan 20220 buys · 11 sells
Repare Therapeutics10% owner · last 12 Jul 20211 buy · 30 sells
Harpoon Therapeutics10% owner · last 5 May 20211 buy · 9 sells
Oncorus10% owner · last 6 Oct 20201 buy · 0 sells
Radius HealthDirector, 10% owner · last 17 Feb 20170 buys · 0 sells
ChiasmaDirector, 10% owner · last 9 Jun 20160 buys · 0 sells
SNDX Syndax Pharmaceuticals10% owner · Biotechnology · last 8 Mar 20160 buys · 0 sells
Aratana Therapeutics10% owner · last 7 Mar 20140 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—1,314,262filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—5,914,197filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—1,577,119filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—5,000,000 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—22,500,000 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—6,000,000 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Bought$20.0M1,112,777 at $18.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—5,000,000 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—22,500,000 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code C—6,000,000 at $0.00filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—1,314,262filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—5,914,197filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Code C—1,577,119filing
12 Jan 2026filed 14 Jan 2026AKTS Aktis OncologyBiotechnologySEC FORM 4 Bought$20.0M1,112,777 at $18.00filing
1 Jun 2023filed 5 Jun 2023Tcr2 TherapeuticsSEC FORM 4 Code J—304,001 at $0.00filing
1 Jun 2023filed 5 Jun 2023Tcr2 TherapeuticsSEC FORM 4 Code J—3,854,963 at $0.00filing
1 Jun 2023filed 5 Jun 2023Tcr2 TherapeuticsSEC FORM 4 Code J—3,370,982 at $0.00filing
22 May 2023filed 24 May 2023Tcr2 Therapeuticsoption or derivativeSEC FORM 4 Code X—42,761 at $0.00filing
22 May 2023filed 24 May 2023Tcr2 Therapeuticsoption or derivativeSEC FORM 4 Code X—135,508 at $0.00filing
22 May 2023filed 24 May 2023Tcr2 TherapeuticsSEC FORM 4 Code X$132K178,269 at $0.74filing

Sectors

Health Care23
Not placed80

Buys in green, sells in red, by the company’s sector.

Related people

Akos CzibereChief Medical Officer · Chief Medical Officer at Aktis Oncology, filing Form 4 there in the last year
Ken HerrmannDirector · Director at Aktis Oncology, filing Form 4 there in the last year
Shulamit Ron-BiggerChief Operating Officer · Chief Operating Officer at Aktis Oncology, filing Form 4 there in the last year
Glenn GormleyDirector · Director at Aktis Oncology, filing Form 4 there in the last year
MPM BIOVENTURES 2018, L.P.10% owner · 10% owner at Aktis Oncology, filing Form 4 there in the last year
Lauren RikerSenior Vice President, Finance · Also traded PCRX in the last 90 days
Dan PatersonPresident and CEO · Also traded VSTM in the last 90 days
Daniel CalkinsChief Financial Officer · Also traded VSTM in the last 90 days